{"id":"nct:NCT07142954","kind":"trial","title":"Epidemiology and Biomarker Study in Alzheimer's Disease","authors":["Eli Lilly and Company"],"author_count":1,"year":2025,"published":"2025-08-27","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07142954","source_url":"https://clinicaltrials.gov/study/NCT07142954","archive_url":"https://space-kitty.com/papers/nct:NCT07142954","updated":"2026-07-07","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer Disease"],"details":{"acronym":"ANCHOR-AD","status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":3400,"sponsor":"Eli Lilly and Company","conditions":["Alzheimer Disease"],"interventions":["OTHER: P-tau217 Test"],"start_date":"2025-08-25","start_date_type":"ACTUAL","primary_completion_date":"2033-07-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}